Table 2

Changes in rheumatoid arthritis activity measures during the study

Measure (possible range)BaselineFollow-upMean changeSRM (95% CI)Mean change by improvement categoryp (ANOVA)
ImprovedStayed the sameWorsened
Patient global assessment (0–100)55.6±25.237.6±24.0−18.0±26.4−0.68 (−0.60 to −0.77)−24.7−7.23.1<0.0001
Pain (0–100)60.5±25.339.7±27.0−21.0±30.3−0.69 (−0.61 to −0.78)−29.7−8.22.2<0.0001
HAQ (0–3)1.4±0.71.0±0.7−0.4±0.6−0.65 (−0.58 to −0.72)−0.63−0.080.06<0.0001
DAS28-ESR (0–9.4)6.16±1.24.84±1.38−1.31±1.34−0.98 (−0.90 to −1.07)−1.67−0.62−0.2<0.0001
DAS28-CRP (1–9.4)5.55±1.094.34±1.26−1.23±1.30−0.95 (−0.87 to −1.04)−1.60−0.59−0.06<0.0001
SDAI (0–86)38.6±14.824.0±13.9−14.9±15.3−0.97 (−0.90 to −1.07)−19.3−7.4−1.28<0.0001
CDAI (0–76)36.8±13.523.0±13.6−13.7±14.1−0.98 (−0.90 to −1.08)−18.0−6.7−1.2<0.0001
  • Plus–minus values are mean±SD.

  • ANOVA, analysis of variance; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28 C-reactive Protein; DAS28-ESR, Disease Activity Score 28 Erythrocyte Sedimentation Rate; HAQ, Health Assessment Questionnaire Disability Index; SDAI, Simplified Disease Activity Index; SRM, standardised response mean.